“The completion of this transaction uniquely positions Johnson & Johnson as a Pharmaceutical and MedTech company focused on delivering transformative healthcare solutions to patients,” said Joaquin Duato, chairman of the board and chief executive officer.
Johnson & Johnson will now present its Consumer Health business financial results as discontinued operations, including a gain of approximately $20 billion in the third quarter of 2023.
The company reported it generated $42.41B in sales for the first six months of its fiscal year. Adjusted earnings per share were $4.97.
JNJ also updated its guidance. It now sees adjusted operational sales up 6.7% excluding the Consumer Health business, which compares to the previous forecast of +6.5% including the Consumer Health business.
Operational sales are seen in the range of $83.6-84.4B post-Kenvue separation, which compares to the previous $99.3-100.3B.
Adjusted EPS is now seen at $10.05 vs. the prior $10.75.
“Following completion of the Kenvue exchange offer, the Company has reduced its outstanding share count by the approximately 191 million shares of common stock accepted in the exchange offer,” JNJ added.
The company secured $13.2B proceeds from the Kenvue debt offering and IPO, while maintaining a 9.5% equity stake in the new company.
JNJ also maintained its quarterly dividend of $1.19 per share.
Add Chart to Comment
We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:
- Enrich the conversation
- Stay focused and on track. Only post material that’s relevant to the topic being discussed.
- Be respectful. Even negative opinions can be framed positively and diplomatically.
- Use standard writing style. Include punctuation and upper and lower cases.
- NOTE: Spam and/or promotional messages and links within a comment will be removed
- Avoid profanity, slander or personal attacks directed at an author or another user.
- Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
- Only English comments will be allowed.
Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.